Board of Directors

Dr. Nelson served as a member on the Board of Directors at Medtronic beginning in 1980. He joined Medtronic as Executive Vice President in 1986 and was elected Vice Chairman in 1988, a position he held until his retirement. Before joining Medtronic, Dr. Nelson practiced surgery from 1969 to 1986, and served as Chairman of the Board and Chief Executive Officer for American MedCenters, Inc. from 1984 to 1986. From 1975 to 1986, he also served as Chairman, President and Chief Executive Officer of Park Nicollet Medical Center, a large multi-specialty group practice in Minneapolis. Dr. Nelson received his Bachelor of Arts Degree from Harvard College in 1959 and his M.D. Degree from the University of Minnesota in 1963. He completed his training in general surgery at Hennepin County General Hospital, Minneapolis, in 1969. Dr. Nelson currently serves on seven corporate boards.

Mr. Petrucci is currently a Senior VP of Investments at RBC Wealth Management. From 1967 to 2006 Mr. Petrucci worked as an Investment Executive at Piper Jaffray. Mr. Petrucci served on the Piper Jaffray Board of Directors from 1981 to 1995. After Piper Jaffray was acquired by UBS Financial Services, Mr. Petrucci became Senior VP of Investments at UBS Financial Services. Mr. Petrucci has earned the Fred Sirianni Award, honoring the top-producing investment executive at U.S. Bancorp Piper Jaffray, 13 years since the award was established 25 years ago. Mr. Petrucci has served on the Board of Directors for the St. Cloud University Foundation, National Urology Board, American Neck and Back, Reliant Technologies, Lettieri’s, Arboretum Foundation, Stemedica Cell Technology and Animal Cell Technology Boards. Mr. Petrucci is a graduate of St. Cloud State University and did his graduate work in Finance at the University of Minnesota. He is also a graduate of the Wharton School of Securities Industry Institute at the University of Pennsylvania.

Mr. Blackey is the President and Chief Operating Office (COO) of Holiday Companies, a leader in the petroleum and convenience store industry with over $2 billion in revenues. Prior to joining Holiday Companies in 2004, Mr. Blackey was a Senior Partner at the accounting firms of Arthur Anderson LLP and Ernst & Young LLP. Mr. Blackey was instrumental in leading several clients through both initial and secondary public offerings, and played a key role in numerous transactions with clients Target Corporation, Carlson Companies, Polaris Industries and CH Robinson Worldwide, among others.

Mr. Friedman is the Managing Partner of Easton Capital Investment Group. Prior to founding Easton Capital, Mr. Friedman was the founder and Managing General Partner of Security Pacific Capital Investors, a $200 million private equity fund geared towards expansion financings and recapitalizations. Previous to Security Pacific, he was a Managing Director and Partner at E.M. Warburg, Pincus & Co., Inc. Mr. Friedman also served as a Managing Director of Atrium Capital Corp., an investment firm. He holds a J.D. degree from Yale Law School and a B.A. degree from Yale College. Mr. Friedman currently serves on the Boards of Renovis, Trellis Bioscience, Xoft, Inc., Sanarus, Inc., YM BioSciences and Assistive Technology. He is Co-Chairman of the Cold Spring Harbor President’s Council.

Dr. Hartzler gained international prominence as a cardiologist during 23 years of practice in interventional cardiology. He served most recently, from 1980 to 1995, as a consulting cardiologist with the Mid America Heart Institute of St. Luke’s Hospital in Kansas City, MO. Dr. Hartzler was the co-founder and director of four medical device companies, including Ventritex Inc. and IntraLuminal Therapeutics, Inc., and served as a consultant and/or director to seven additional companies, some of which were medical device companies. Dr. Hartzler has published numerous articles in medical and scientific journals on various aspects of cardiology, and has been a frequent lecturer on these topics. Dr. Hartzler is regarded as one of the pioneers of interventional cardiology.

Dr. Howe founded five successful start-up ventures in the medical technology and information systems business sector over the past twenty-five years. Dr. Howe currently serves as Chairman of the Board and Chief Financial Officer of Stemedica Cell Technologies, an adult stem cell company. Dr. Howe was the former Chairman and CFO of Reliant Technologies, a medical laser company. Dr. Howe was the CEO and Founder of National Information Systems, Inc., a leading customer and marketing research company and Metrix Communications an Internet company that developed Manufacturing, and Supply Chain Management Systems. Dr. Howe is an investor in several ventures and serves on the Board of Directors for several companies including BioPharma Scientific and Americas Back Medical Clinic.

Mr. Martin has been a driver in building shareholder value throughout the last ten years in three companies. Mr. Martin was appointed CSI’s Chief Executive Officer in February 2007 and has served on the board since August 15, 2006. Prior to that, Mr. Martin was Chief Operating Officer for FoxHollow Technologies, (IPO 2004) where he directed their commercial plan. Prior to FoxHollow, Mr. Martin was VP of Global Sales for Rita Medical Systems, (IPO 2000) and before that was Director of U.S. Sales for CardioThoracic Systems, (IPO 1996). Mr. Martin has also held sales and sales management positions for Procter & Gamble, Boston Scientific and Guidant Corporation. Mr. Martin currently serves on two boards.

Gus Lawlor has been a managing director of HealthCare Ventures since 2000. He was previously Chief Operating Officer of LeukoSite, Inc., a HealthCare Ventures III, IV, and V company. Before joining LeukoSite, he was Chief Financial Officer and Vice President of Corporate Development for Alpha-Beta Technology. He held similar positions at BioSurface Technology and Armstrong Pharmaceuticals. He was previously a management consultant with KPMG Peat Marwick. Mr. Lawlor is a member of the board of directors of the Slater Center in Providence, Rhode Island. He received a master’s degree in public and private management from Yale University.

Prior to joining TPG Biotech in 2007, Mr. Brown co-founded Healthcare Investment Partners, or HIP, a private equity fund focused exclusively on healthcare, and served as a Managing Director of HIP since its inception in June 2004. Before forming HIP, Mr. Brown had over seventeen years of experience in healthcare investment banking, most recently as a Managing Director at Credit Suisse First Boston, where he led the firm’s West Coast healthcare effort and was one of the senior partners responsible for the firm’s global life sciences practice, from August 2000 to June 2004. Mr. Brown serves on the board of directors of Angiotech Pharmaceuticals, Inc., Oculus Innovative Sciences, and Replidyne, Inc. Mr. Brown received a B.A. in English from Middlebury College and an M.B.A. from UCLA, and attended graduate school at Oxford University in English Literature.